A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs RGX 314 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors REGENXBIO
- 08 Nov 2017 According to a REGENXBIO media release, following a scheduled review by an independent Data Safety and Monitoring Board (DSMB), the Company expects to initiate dosing of the third cohort in the Phase I clinical trial by the first quarter of 2018.
- 08 Nov 2017 According to a REGENXBIO media release, dosing of second cohort has been completed. A total of 12 patients, from four different sites, have now been treated in the trial.
- 20 Sep 2017 According to a REGENXBIO media release, the company plans to share an interim trial update by the end of 2017.